Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 105

1.

Increased degradation of ATP is driven by memory regulatory T cells in kidney transplantation tolerance.

Durand M, Dubois F, Dejou C, Durand E, Danger R, Chesneau M, Brosseau C, Guerif P, Soulillou JP, Degauque N, Eliaou JF, Giral M, Bonnefoy N, Brouard S.

Kidney Int. 2018 May;93(5):1154-1164. doi: 10.1016/j.kint.2017.12.004. Epub 2018 Feb 15.

PMID:
29455908
2.

The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway.

Laprevotte E, Cochaud S, du Manoir S, Lapierre M, Dejou C, Philippe M, Giustiniani J, Frewer KA, Sanders AJ, Jiang WG, Michaud HA, Colombo PE, Bensussan A, Alberici G, Bastid J, Eliaou JF, Bonnefoy N.

Oncotarget. 2017 Dec 6;8(69):113360-113372. doi: 10.18632/oncotarget.23008. eCollection 2017 Dec 26.

3.

IL-21 promotes the development of a CD73-positive Vγ9Vδ2 T cell regulatory population.

Barjon C, Michaud HA, Fages A, Dejou C, Zampieri A, They L, Gennetier A, Sanchez F, Gros L, Eliaou JF, Bonnefoy N, Lafont V.

Oncoimmunology. 2017 Oct 4;7(1):e1379642. doi: 10.1080/2162402X.2017.1379642. eCollection 2017.

4.

PD-1 blockade at the time of tumor escape potentiates the immune-mediated antitumor effects of a melanoma-targeting monoclonal antibody.

They L, Michaud HA, Becquart O, Lafont V, Guillot B, Boissière-Michot F, Jarlier M, Mollevi C, Eliaou JF, Bonnefoy N, Gros L.

Oncoimmunology. 2017 Jul 20;6(10):e1353857. doi: 10.1080/2162402X.2017.1353857. eCollection 2017.

5.

Impact of KIR/HLA genetic combinations on double umbilical cord blood transplantation outcomes. Results of a French multicentric retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and the Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI).

Rettman P, Malard F, Legrand N, Avinens O, Eliaou JF, Picard C, Dormoy A, Lafarge X, de Matteis M, Kennel A, Loiseau P, Devys A, Boudifa A, Absi L, Fort M, Masson D, Quainon F, Theodorou I, Batho A, Parissiadis A, Delbos F, Drouet M, Senitzer D, Marry E, Raus N, Yakoub-Agha I, Cesbron A, Retière C, Gagne K.

Bone Marrow Transplant. 2016 Nov;51(11):1499-1503. doi: 10.1038/bmt.2016.151. Epub 2016 Jun 6. No abstract available.

PMID:
27272444
6.

Effects of alcohol withdrawal on monocyte subset defects in chronic alcohol users.

Donnadieu-Rigole H, Mura T, Portales P, Duroux-Richard I, Bouthier M, Eliaou JF, Perney P, Apparailly F.

J Leukoc Biol. 2016 Nov;100(5):1191-1199. Epub 2016 Jun 2.

PMID:
27256567
7.

Association of HLA-A and Non-Classical HLA Class I Alleles.

Carlini F, Ferreira V, Buhler S, Tous A, Eliaou JF, René C, Chiaroni J, Picard C, Di Cristofaro J.

PLoS One. 2016 Oct 4;11(10):e0163570. doi: 10.1371/journal.pone.0163570. eCollection 2016.

8.

Corrigendum to "One of the Immune Activation Profiles Observed in HIV-1-Infected Adults with Suppressed Viremia is Linked to Metabolic Syndrome: The ACTIVIH Study" [EBioMedicine 8 (2016) 265-276].

Psomas C, Younas M, Reynes C, Cezar R, Portalès P, Tuaillon E, Guigues A, Merle C, Atoui N, Fernandez C, Le Moing V, Barbuat C, Marin G, Nagot N, Sotto A, Eliaou JF, Sabatier R, Reynes J, Corbeau P.

EBioMedicine. 2016 Aug;10:318-322. doi: 10.1016/j.ebiom.2016.08.003. Epub 2016 Aug 4. No abstract available.

9.

One of the immune activation profiles observed in HIV-1-infected adults with suppressed viremia is linked to metabolic syndrome: The ACTIVIH study.

Psomas C, Younas M, Reynes C, Cezar R, Portalès P, Tuaillon E, Guigues A, Merle C, Atoui N, Fernandez C, Le Moing V, Barbuat C, Marin G, Nagot N, Sotto A, Eliaou JF, Sabatier R, Reynes J, Corbeau P.

EBioMedicine. 2016 Jun;8:265-276. doi: 10.1016/j.ebiom.2016.05.008. Epub 2016 May 10.

10.

Expression of classical HLA class I molecules: regulation and clinical impacts: Julia Bodmer Award Review 2015.

René C, Lozano C, Eliaou JF.

HLA. 2016 May;87(5):338-49. doi: 10.1111/tan.12787. Epub 2016 Apr 6. Review.

PMID:
27060357
11.

Narcolepsy-Associated HLA Class I Alleles Implicate Cell-Mediated Cytotoxicity.

Tafti M, Lammers GJ, Dauvilliers Y, Overeem S, Mayer G, Nowak J, Pfister C, Dubois V, Eliaou JF, Eberhard HP, Liblau R, Wierzbicka A, Geisler P, Bassetti CL, Mathis J, Lecendreux M, Khatami R, Heinzer R, Haba-Rubio J, Feketeova E, Baumann CR, Kutalik Z, Tiercy JM.

Sleep. 2016 Mar 1;39(3):581-7. doi: 10.5665/sleep.5532.

12.

5' and 3' untranslated regions contribute to the differential expression of specific HLA-A alleles.

René C, Lozano C, Villalba M, Eliaou JF.

Eur J Immunol. 2015 Dec;45(12):3454-63. doi: 10.1002/eji.201545927. Epub 2015 Oct 13.

13.

CD39: A complementary target to immune checkpoints to counteract tumor-mediated immunosuppression.

Bonnefoy N, Bastid J, Alberici G, Bensussan A, Eliaou JF.

Oncoimmunology. 2015 Feb 3;4(5):e1003015. eCollection 2015 May.

14.

IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells.

Mombelli S, Cochaud S, Merrouche Y, Garbar C, Antonicelli F, Laprevotte E, Alberici G, Bonnefoy N, Eliaou JF, Bastid J, Bensussan A, Giustiniani J.

Sci Rep. 2015 Jul 8;5:11874. doi: 10.1038/srep11874.

15.

Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity.

Michaud HA, Eliaou JF, Lafont V, Bonnefoy N, Gros L.

Oncoimmunology. 2014 Dec 13;3(9):e955684. eCollection 2014 Oct. Review.

16.

Emerging clinical phenotypes associated with anti-cytokine autoantibodies.

Vincent T, Plawecki M, Goulabchand R, Guilpain P, Eliaou JF.

Autoimmun Rev. 2015 Jun;14(6):528-35. doi: 10.1016/j.autrev.2015.01.015. Epub 2015 Jan 26. Review.

PMID:
25633324
17.

Plasticity of γδ T Cells: Impact on the Anti-Tumor Response.

Lafont V, Sanchez F, Laprevotte E, Michaud HA, Gros L, Eliaou JF, Bonnefoy N.

Front Immunol. 2014 Dec 8;5:622. doi: 10.3389/fimmu.2014.00622. eCollection 2014. Review.

18.

Follow-up of post-transplant minimal residual disease and chimerism in childhood lymphoblastic leukaemia: 90 d to react.

Pochon C, Oger E, Michel G, Dalle JH, Salmon A, Nelken B, Bertrand Y, Cavé H, Cayuela JM, Grardel N, Macintyre E, Margueritte G, Méchinaud F, Rohrlich P, Paillard C, Demeocq F, Schneider P, Plantaz D, Poirée M, Eliaou JF, Semana G, Drunat S, Jonveaux P, Bordigoni P, Gandemer V.

Br J Haematol. 2015 Apr;169(2):249-61. doi: 10.1111/bjh.13272. Epub 2014 Dec 19.

PMID:
25522886
19.

Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.

Bastid J, Regairaz A, Bonnefoy N, Déjou C, Giustiniani J, Laheurte C, Cochaud S, Laprevotte E, Funck-Brentano E, Hemon P, Gros L, Bec N, Larroque C, Alberici G, Bensussan A, Eliaou JF.

Cancer Immunol Res. 2015 Mar;3(3):254-65. doi: 10.1158/2326-6066.CIR-14-0018. Epub 2014 Nov 17.

20.

Is there any impact of HLA-DPB1 disparity in 10/10 HLA-matched unrelated hematopoietic SCT? Results of a French multicentric retrospective study.

Gagne K, Loiseau P, Dubois V, Dufossé F, Perrier P, Dormoy A, Jollet I, Renac V, Masson D, Picard C, Lafarge X, Hanau D, Quainon F, Delbos F, Coeffic B, Absi L, Eliaou JF, Moalic V, Fort M, de Matteis M, Theodorou I, Hau F, Batho A, Pedron B, Caillat-Zucman S, Marry E, Raus N, Yakoub-Agha I, Cesbron A.

Bone Marrow Transplant. 2015 Feb;50(2):232-6. doi: 10.1038/bmt.2014.253. Epub 2014 Nov 3.

PMID:
25365066

Supplemental Content

Loading ...
Support Center